Gastrostomy dependence in head and neck carcinoma patient receiving post-operative therapy

Jpn J Clin Oncol. 2014 Nov;44(11):1058-62. doi: 10.1093/jjco/hyu118. Epub 2014 Aug 21.

Abstract

Objective: Post-operative concurrent chemoradiotherapy significantly improves the rates of locoregional control and disease-free survival in high-risk patients but has significant adverse effects. Percutaneous endoscopic gastrostomy and opioid-based pain control increase treatment completion rates but can result in dysphagia.

Methods: The rate and duration of use of prophylactically placed percutaneous endoscopic gastrostomies were evaluated in 43 patients who underwent post-operative radiotherapy or chemoradiotherapy from April 2007 through March 2010. All patients completed treatment and received 60 Gy or more of radiotherapy.

Results: Thirty four of 43 patients (79.1%) used percutaneous endoscopic gastrostomies, which could later be removed in 25 of 34 patients. The median period of use was 108 days. Only one disease-free patient was permanently dependent on percutaneous endoscopic gastrostomy feeding. The frequency of percutaneous endoscopic gastrostomy use among patients with oral, oropharyngeal and hypopharyngeal cancer was 91.7, 100 and 54.5%, respectively.

Conclusions: Prolonged percutaneous endoscopic gastrostomy use is not required in patients receiving post-operative chemoradiotherapy and will not lead to dysphagia.

Keywords: H and N-RadOncol; deglutition training; enteral feeding; nutritional management; post-operative therapy; prophylactic PEG.

MeSH terms

  • Adult
  • Aged
  • Carcinoma, Squamous Cell / surgery
  • Carcinoma, Squamous Cell / therapy*
  • Chemoradiotherapy
  • Chemotherapy, Adjuvant
  • Deglutition Disorders / etiology
  • Disease-Free Survival
  • Dose Fractionation, Radiation
  • Dysgeusia / etiology
  • Enteral Nutrition / methods
  • Female
  • Gastrostomy*
  • Head and Neck Neoplasms / surgery
  • Head and Neck Neoplasms / therapy*
  • Humans
  • Male
  • Middle Aged
  • Oropharyngeal Neoplasms / therapy
  • Radiotherapy, Adjuvant
  • Squamous Cell Carcinoma of Head and Neck